The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis
With over 85 microbiome-based, live biotherapeutic products under preclinical and clinical development, the demand for R&D and manufacturing services for such products is anticipated to increase beyond the capabilities of innovator companies alone London Roots Analysis has announced the addition of “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients … Continue reading The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis Continue Reading
Although hazardous reaction chemistries are not used during early drug development stages owing to the associated risks, they offer a wide range of benefits over traditional approaches, especially from the perspective of large-scale manufacturing Roots Analysis is pleased to announce the publication of its recent study, titled, “High Energy Chemistry / Hazardous Chemistry-based API Manufacturing …